The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.

The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.

The invention relates to a process for preparing a monolysinate compound (200, 300, 400, 500, 600, 700, 800, 900). The process comprises providing (502) a liquid reaction mixture (810), in which lysine (802) and a metal salt (404) are dissolved; reacting the lysine dissolved in the reaction mixture and the metal salt to form the monolysinate compound; and drying the liquid reaction mixture in order to obtain the monolysinate compound.

The invention relates to a process for preparing a monolysinate compound (200, 300, 400, 500, 600, 700, 800, 900). The process comprises providing (502) a liquid reaction mixture (810), in which lysine (802) and a metal salt (404) are dissolved; reacting the lysine dissolved in the reaction mixture and the metal salt to form the monolysinate compound; and drying the liquid reaction mixture in order to obtain the monolysinate compound.

An amorphous form of a chelating agent is provided, in particular wherein the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS), hydroxamic acid, oxalic acid, galactaric acid, metaphosphoric acid, or phytic acid, or a salt of any one or more of the above acids, or a mixture of two or more of any of the above acids or salts thereof.

A process for preparing an amorphous form of a chelating agent comprises the steps of: a) Dissolving the chelating agent in a suitable solvent; b) Optionally purifying the solution; c) Isolating an amorphous form of the chelating agent; d) Optionally post drying or conditioning the amorphous form of the chelating agent.

An amorphous form of a chelating agent is provided, in particular wherein the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS), hydroxamic acid, oxalic acid, galactaric acid, metaphosphoric acid, or phytic acid, or a salt of any one or more of the above acids, or a mixture of two or more of any of the above acids or salts thereof.

A process for preparing an amorphous form of a chelating agent comprises the steps of: a) Dissolving the chelating agent in a suitable solvent; b) Optionally purifying the solution; c) Isolating an amorphous form of the chelating agent; d) Optionally post drying or conditioning the amorphous form of the chelating agent.

The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like. It was confirmed that the novel magnesium-serinate composition obtained by the production method of the present invention consisted of about 10% magnesium and about 90% serine, as determined by instrumental analysis, was solubilized at a concentration of about 500 mg/ml in water at room temperature at a pH of 6.0 to 10.0, was maintained in an aqueous solution state without forming a precipitate, and was also solubilized at a concentration of about 500 mg/ml in phosphate-buffered saline (PBS) solution at room temperature without forming a precipitate. Thus, the novel magnesium-serinate composition has properties suitable for administration orally or by injection to the human body. In addition, the compound activates mitochondrial function and neuronal cell proliferation by increasing the oxygen consumption rate of mitochondria, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, etc.

A zinc ascorbate glycinate co-salt having a formula of MC8H11NO8 and a suggested structure of: Formula (I). Where M is Ca, Mg, or Zn. The divalent metal ascorbate glycinate co-salt is formed as a powder having a metal content of about 8% to about 21% on an anhydrous basis and containing between 0.0-20.0% water.

A zinc ascorbate glycinate co-salt having a formula of MC8H11NO8 and a suggested structure of: Formula (I). Where M is Ca, Mg, or Zn. The divalent metal ascorbate glycinate co-salt is formed as a powder having a metal content of about 8% to about 21% on an anhydrous basis and containing between 0.0-20.0% water.

##STR00001##

A magnesium citrate glycinate co-salt has a formula of Mg.sub.2C.sub.8H.sub.9NO.sub.9—XH.sub.2O and a suggested structure of: ##STR00001## The magnesium citrate glycinate co-salt has an apparent density of 1740 kg/m.sup.3 and is compressible in a range of compression pressures from approximately 50 MPa to approximately 150 MPa. The magnesium citrate glycinate co-salt is formed by combining citric acid and glycine in a 1:1 molar ratio to form an aqueous reaction mixture and neutralizing the aqueous reaction mixture with a magnesium source having a magnesium:ligand ratio of 1:1.